Physician profile
Charles Hasbrook
NPI 1760580526
$986.88
in general payments reported to CMS, 2019-2025
11 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $70.55 · 2021: $28.02 · 2022: $204 · 2023: $166 · 2024: $169 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $445.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $180.26 | 2023-2025 | Trelegy Ellipta |
| Abbvie INC. | $116.46 | 2021-2022 | |
| Astellas Pharma US INC | $58.32 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.69 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $40.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.91 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $18.92 | 2024 | Edarbi |
| Sumitomo Pharma America, INC. | $16.06 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $11.88 | 2019 | |
| Pfizer INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Hasbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.